Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Vaccine ; 17(1): 59-63, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10078608

ABSTRACT

Synthesized T-cell epitopes of tetanus toxin are universally immunogenic and serve to enhance immune response when they are used as vaccine carriers of B-cell epitopes. The immunogenicity of the P2, P30, and P2P30 T-cell epitopes of tetanus toxin and whole tetanus toxoid (TT) was evaluated by in vitro proliferation assay of lymphocytes from men with no history of tetanus vaccination who were enrolled in a malaria prophylaxis trial. The enhancement of immune response by tetanus vaccination (Td) and possible antagonism by the antimalarial drugs, was measured by pre- and post-Td comparisons within and between immunized prophylaxis groups (primaquine, chloroquine, placebo) and a nonimmunized control group. Constructs demonstrated low immunogenicity relative to TT in all groups. Relative to both control and its own baseline, the immunized primaquine prophylaxis group was distinct in demonstrating significantly increased proliferation against all three subunits and at both high (30 microg ml(-1)) and low (3 microg ml(-1)) concentrations. Immunization elicited significantly increased proliferation responses by placebo and chloroquine prophylaxis groups against only the P2P30 construct. Despite these significant post-Td changes, a low concentration of TT 0.1 microg ml(-1)) stimulated proliferation 7-10 times over that induced by the greatest concentration of the constructs.


Subject(s)
Antimalarials/therapeutic use , Chloroquine/therapeutic use , Epitopes, T-Lymphocyte/immunology , Lymphocyte Activation/immunology , Malaria/prevention & control , Primaquine/therapeutic use , Tetanus Toxin/immunology , Tetanus Toxoid/immunology , Adult , Amino Acid Sequence , Humans , Malaria/immunology , Male , Molecular Sequence Data , Placebos , T-Lymphocytes/immunology , Tetanus Toxin/pharmacology , Tetanus Toxoid/pharmacology
2.
Clin Diagn Lab Immunol ; 5(5): 721-4, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9729542

ABSTRACT

To examine the role of the Plasmodium falciparum Exp-1 blood-stage protein in producing antibodies that cross-react with human T-cell lymphotropic virus type I (HTLV-I) proteins, we studied sera from Indonesian volunteers who seroconverted to malaria after transmigrating to an area where malaria is hyperendemic. Samples from Philippine volunteers, that were used in a prior study that examined malaria antibodies that cross-react with HTLV-I proteins, were also used. Eighty-three percent of the Indonesian transmigrants developed antibodies against the malaria Exp-1 protein by 6 months postmigration. Of these malaria seroconverters, 27% developed false-positive HTLV-I enzyme immunoassay (EIA) immunoreactivity, as indicated by indeterminate HTLV-I Western blot banding patterns. Five of the six Philippine samples tested were HTLV-I EIA false positive and Western blot indeterminate. When a recombinant Exp-1 protein was used in blocking experiments, the HTLV-I Western blot immunoreactivity of sera from both groups was either completely eliminated or greatly reduced. No effect on the Western blot immunoreactivity of truly HTLV-I-positive sera was seen. To determine if immunization with the recombinant Exp-1 protein could elicit the production of HTLV-I antibodies, six mice were inoculated with the recombinant protein. Following administration of three 50-microgram doses of the protein, four of the six mice developed antibodies that cross-reacted with HTLV-I proteins on Western blot. These results indicate that the immune response against the malaria Exp-1 protein may result in HTLV-I-cross-reacting antibodies that can lead to false-positive EIA and indeterminant Western blotting results.


Subject(s)
Antibodies, Protozoan/immunology , Antigens, Protozoan/immunology , Cross Reactions/immunology , HTLV-I Antigens/immunology , Plasmodium falciparum/immunology , Protozoan Proteins/immunology , Viral Proteins/immunology , Animals , Antibodies, Protozoan/blood , Antibodies, Viral/blood , Antibodies, Viral/immunology , Blotting, Western , HTLV-I Antibodies/blood , Humans , Immunoenzyme Techniques , Indonesia , Mice , Recombinant Proteins/genetics , Recombinant Proteins/immunology
3.
J Infect Dis ; 176(6): 1644-8, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9395384

ABSTRACT

Immune suppression, a potential side effect of long-term chemoprophylaxis, was evaluated as part of a randomized, placebo-controlled trial that compared daily primaquine against weekly chloroquine for malaria prevention. In the last month of the year-long trial, baseline in vitro lymphoproliferative responses to tetanus toxoid were measured, and a tetanus-diphtheria (Td) immunization was administered. Proliferative responses to tetanus toxoid in each Td-immunized group increased significantly over pre-Td baselines and those of the unvaccinated control. Highest initial responses were measured in the primaquine group. The proportion of responders and the magnitude of proliferation was consistently low in the chloroquine group, and end point responses in this group were significantly below those of the placebo. These results suggest that the development and duration of the cellular response to tetanus immunization was impaired by long-term weekly chloroquine prophylaxis, while daily primaquine prophylaxis over the same time period had no inhibitory effect.


Subject(s)
Antimalarials/adverse effects , Chloroquine/adverse effects , Diphtheria Toxoid/immunology , Lymphocyte Activation/drug effects , Primaquine/adverse effects , Tetanus Toxoid/immunology , Adult , Antimalarials/therapeutic use , Chloroquine/therapeutic use , Diphtheria-Tetanus Vaccine , Humans , Immune Tolerance/drug effects , Immunization, Secondary , Immunocompromised Host/immunology , Malaria/prevention & control , Male , Primaquine/therapeutic use , T-Lymphocytes/immunology , Vaccination , Vaccines, Combined/immunology
4.
Antimicrob Agents Chemother ; 40(12): 2737-42, 1996 Dec.
Article in English | MEDLINE | ID: mdl-9124832

ABSTRACT

Immune suppression and disturbances of normal leukocyte populations are side effects attributed to many antimalarial drugs and were concerns during a recent year-long placebo-controlled trial that compared daily primaquine (0.5 mg of base per kg of body weight per day) with weekly chloroquine (300 mg of base one time per week) for malaria prophylaxis. The study took place in Irian Jaya, Indonesia, from July 1994 to August 1995 and enrolled 129 Javanese men with normal glucose-6-phosphate dehydrogenase function. Tests for lymphocyte function and subset composition were conducted blindly on a cross-section of subjects during weeks 10 (n = 42) and 48 (n = 72) of supervised prophylaxis. Lymphocyte function, measured as the proliferative response of peripheral blood mononuclear cells to a panel of mitogens (pokeweed mitogen, phytohemagglutinin, and concanavalin A) and antigens (purified protein derivative of Mycobacterium tuberculosis and Clostridium tetani toxoid) and expressed as a stimulation index, allowed for statistical comparison between groups and sampling times. The lymphocyte subset composition for each group and time point was based on flow cytometry profiling, and the results were expressed as the mean percentages of CD3 (total T cells), CD19 (total B cells), CD4+ (T-helper and inducer cells), and CD8+ (T suppressor and cytotoxic cells), CD3/CD16+ CD56 (natural killer cells), CD3/anti-HLA-DR (activated T cells) cells and the CD4+/CD8+ ratios. Lymphocyte stimulation indices were statistically comparable among the placebo, primaquine, and chloroquine groups at both time points, although the primaquine group was distinguished by having repeatedly greater proportions of subjects with high ( > 3.0) stimulation indices. The lymphocyte subset profiles of these groups at both time points were also similar and undistorted relative to those of healthy reference populations matched for age, sex, and ethnicity. The results provide quantitative support for the safety of daily primaquine prophylaxis.


Subject(s)
Antimalarials/therapeutic use , Chloroquine/therapeutic use , Lymphocyte Activation/drug effects , Lymphocyte Subsets/drug effects , Malaria/prevention & control , Primaquine/therapeutic use , Adult , Antimalarials/administration & dosage , Chloroquine/administration & dosage , Cross-Sectional Studies , Humans , Indonesia , Malaria/blood , Male , Primaquine/administration & dosage
5.
Am J Trop Med Hyg ; 39(3): 232-5, 1988 Sep.
Article in English | MEDLINE | ID: mdl-2459979

ABSTRACT

Most adults in highly malarious areas have antibodies to the repeat region of the circumsporozoite protein of Plasmodium falciparum. To determine if a T cell epitope on the repeat region stimulated T cell help for this antibody, we used R32tet32, a recombinant construct derived from the repeat region of the circumsporozoite protein of P. falciparum, to stimulate in vitro mononuclear cells from residents of an area hyperendemic for malaria. Three groups differing in the length of time they had resided in a malarious area were studied. The percentage of individuals in each group who had positive antibody responses to R32tet32 increased with increased exposure to malaria. However, antibody positivity was not correlated with in vitro lymphocyte proliferation responses to the antigen. Lymphocytes from 79% of the individuals showing serum antibodies to R32tet32 failed to respond in a lymphocyte transformation assay, suggesting that T cell helper activity in these individuals was based upon the recognition of a T cell epitope not located within this peptide.


Subject(s)
Antigens, Protozoan/immunology , Antigens, Surface/immunology , Malaria/immunology , Plasmodium falciparum/immunology , Protozoan Proteins , T-Lymphocytes/immunology , Animals , Antibodies, Protozoan/biosynthesis , Cytotoxicity Tests, Immunologic , Enzyme-Linked Immunosorbent Assay , Epitopes/immunology , Humans , Immunity, Cellular , Lymphocyte Activation , Peptide Fragments/immunology
6.
Antimicrob Agents Chemother ; 21(5): 842-3, 1982 May.
Article in English | MEDLINE | ID: mdl-6808914

ABSTRACT

Of 133 Corynebacterium diphtheriae isolates from diphtheria patients in Jakarta, Indonesia, 86% were resistant to greater than or equal to 32 micrograms of tetracycline per ml. All isolates were sensitive to ampicillin, cephalothin, chloramphenicol, clindamycin, penicillin, erythromycin, and kanamycin. The general resistance of C. diphtheriae to tetracycline in this part of Indonesia appears to be unique compared with resistance reported in studies done in other parts of the world.


Subject(s)
Corynebacterium diphtheriae/drug effects , Diphtheria/microbiology , Tetracycline/pharmacology , Drug Resistance, Microbial , Humans , Indonesia
SELECTION OF CITATIONS
SEARCH DETAIL
...